Global Liposomes Drug Delivery Market Outlook 2022

Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only.
In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.
North America dominated the market with market share of 44% due to the high medical level. Following North America, Europe is the second largest market with market share of 36%. Asian Pacific regions are the third largest market with developed countries like Japan and many developing countries like China. Its market share is about 12%.
Johnson & Johnson, Gilead Sciences, Pacira, Sun Pharmaceutical, Luye Pharma and Sigma-Tau Group are the top 6 players of Liposomes Drug Delivery, with about 77% market shares.

The global Liposomes Drug Delivery market was valued at US$ 3087.7 million in 2020 and is expected to reach US$ 5921.5 million by the end of 2027, growing at a CAGR of 10.0% during 2021-2027.
This report focuses on Liposomes Drug Delivery volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Liposomes Drug Delivery market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Liposomes Drug Delivery Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others

Segment by Application
Fungal Infection Therapy
Cancer & Tumor Therapy
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
Spectrum Pharmaceuticals
Shanghai New Asia